Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-101 for intraoperative detection of colorectal and pancreatic cancer
NCT02973672Phase 2Completed
- Sponsor
- SurgiMab
- Start
- Jan 2016
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sgm-101 in colorectal cancer (CRC) and pancreatic cancer (PC), sponsored by SurgiMab. Primary endpoint: Number of patients with treatment-related adverse events. Started Jan 2016; status: completed.
02
Drugs
sgm-101
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02973672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973672.